Department of Clinical Research, Pasteur Institute of Iran, Tehran, Iran.
Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Nanomedicine (Lond). 2018 Dec;13(24):3129-3147. doi: 10.2217/nnm-2018-0063. Epub 2018 Nov 22.
Improvement in the treatment of Leishmania major's pathological effects through increasing the dose of amphotericin B loaded into nanochitosan.
MATERIALS & METHODS: The phase separation method was used for nanochitosan synthesis and amphotericin loading. Also a novel solvent was designed and the nanodrug efficacy was evaluated in vitro and in vivo (pathology) environments.
The drug loading efficiency of 90%, along with slow drug-release with cellular uptake of 98.6% was achieved. The novel solvent was composed of 10% acetic acid, and it was succeeded to dissolve AK10 mg/kg. Also, AK10 mg/kg had no side effects in in vitro and in vivo environments. In addition, the complete wound healing and parasite inhibition were achieved by using AK10 mg/kg in terms of improvement the treatment indicators.
Increasing the therapeutic dose of AK to 10 mg/kg caused the successful treatment of L. major's pathological effects in in vitro and in vivo environments.
通过增加纳米壳聚糖负载两性霉素 B 的剂量来改善利什曼原虫病理效应的治疗效果。
采用相分离法合成纳米壳聚糖并负载两性霉素 B。还设计了一种新型溶剂，并在体外和体内（病理学）环境中评估了纳米药物的疗效。
实现了 90%的药物载药量，以及 98.6%的细胞摄取的缓慢药物释放。新型溶剂由 10%的乙酸组成，成功溶解了 AK10mg/kg。此外，AK10mg/kg 在体外和体内环境中均无副作用。此外，通过使用 AK10mg/kg，在改善治疗指标方面，完全实现了伤口愈合和寄生虫抑制，从而成功治疗了 L. major 的病理效应。
将 AK 的治疗剂量增加到 10mg/kg 导致在体外和体内环境中成功治疗 L. major 的病理效应。
